Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Financing will support Sense’s development of instrument-free molecular diagnostics aimed at true point-of-care testing
Sense Biodetection Limited raises £12.3m to progress instrument-free molecular diagnostics
Initial focus on diagnosing infectious disease through development of machine-free, lab-quality, True Point-of-Care™ products
SP Industries, Inc., a leading designer and manufacturer of state-of-the-art laboratory equipment, pharmaceutical fill-finish manufacturing solutions, laboratory supplies and glassware, announced that it has acquired the assets of privately held i-Dositecno.
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform
This marks the eighth such extension for the deal.
Edan Diagnostics, Inc., a wholly own subsidiary of Edan Instruments, Inc., a world leader in the development and manufacture of bio-electronic devices and laboratory analyzers for medical diagnostics, and LGC, a global life science tools leader, announced today the sale of LGC’s ClariLight molecular diagnostics POC platform to Edan.
Founder Mike Wenger to Join Staff as Vice President of Patient Engagement
On Thursday, FTC staff reviewing Roche’s $4.8 billion bid for Spark gave the deal a thumbs up after reviewing the potential merger.
Innovative approach for hard-to-treat cancers being developed at the Cancer Research UK Beatson Institute